Gilead Sciences (GILD) Invested Capital (2009 - 2026)

Gilead Sciences (GILD) has reported Invested Capital for 18 consecutive years, with $45.7 billion the latest figure, recorded in Q1 2026.

• Invested Capital for Q1 2026 came in at $45.7 billion, up 3.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $45.7 billion (up 3.77% YoY), and the FY2025 annual result was $47.6 billion, up 3.66% from the prior year.
• Invested Capital was $45.7 billion for Q1 2026 at Gilead Sciences, down from $47.6 billion in the prior quarter.
• Over five years, Invested Capital peaked at $47.7 billion in Q4 2023 and troughed at $41.5 billion in Q2 2024.
• Average Invested Capital over 5 years is $45.5 billion, with a median of $46.2 billion recorded in 2023.
• Year-over-year, Invested Capital dropped 11.83% in 2024 and rose 11.63% in 2025.
• Over 5 years, Invested Capital stood at $46.4 billion in 2022, then climbed by 2.8% to $47.7 billion in 2023, then decreased by 3.73% to $46.0 billion in 2024, then climbed by 3.66% to $47.6 billion in 2025, then fell by 4.1% to $45.7 billion in 2026.
• Per Business Quant data, the three most recent Invested Capital figures were $45.7 billion in Q1 2026, $47.6 billion in Q4 2025, and $46.5 billion in Q3 2025.